-
O S Levin,
O S Nesterova,
O V Otcheskaia,
E Iu Zhuravleva,
I Iu Artemova, A A Khozova,
A M Ismailov,
L N Lisenker,
T V Vdovichenko,
L D Rotor,
P A Ganzula,
A K Ivanov,
A N Boĭko
[show abstract]
[hide abstract]
ABSTRACT: The open 3-month study of influence of D2/D3 dopamine agonist pramipexole on of Parkinson's disease (PD) features, which are relatively resistant to traditional dopaminergic therapy: tremor, affective and cognitive impairment, has been conducted. Ninety-eight patients with PD, aged from 42 to 75 years (mean age 63,2+/-10,2 years), have been included in the study. Twenty percents of patients included were older than 70 years. The Hoehn and Yahr stage varied from 1 to 4 (men stage 2,5+/-0,8). Seventy percents of patients received levodopa (mean dosage 351,2+/-279,4 mg); 62% had motor fluctuations and 43% - dyskinesias. Pramipexole was titrated to effective dose (maximum 3 mg/d, mean 2,1 mg/d). The decrease of resting tremor by 50% and postural and kinetic tremor (assessed with the UPDRS and spiralography) by 37% was noticed to the end of 3 month. The severity of depressive symptoms measured with the Montgomery-Asberg scale and a modified version of the Geriatric Depression scale was reduced by one third. The statistically significant decrease of motor fluctuations and dyskinesias, increase of verbal fluency (but not other cognitive functions) were also found. The clinically significant effect of reducing of motor and non-motor symptoms was seen in 86% patients regardless of their age, illness duration, severity of motor deficit and affective and cognitive disturbances. The fair tolerability of the drug was shown including patients older than 70 years.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 02/2009; 109(8):36-41. · 0.12 Impact Factor
-
T T Batysheva,
L V Bagir,
E V Kostenko,
I Yu Artemova,
T V Vdovichenko,
P A Ganzhula,
E Yu Zhuravleva,
A M Ismailov,
L N Lisenker,
O V Nesterova,
O V Otcheskaya,
L D Rotor, A A Khozova,
A N Boiko
Neuroscience and Behavioral Physiology 02/2009; 39(2):193-7.
-
A N Boĭko,
T T Batysheva,
N G Minaeva,
L A Babina,
T V Vdovichenko,
E Iu Zhuravleva,
R K Shikhkerimov,
E A Malykhina, A A Khozova,
K A Zaĭtsev,
E V Kostenko
[show abstract]
[hide abstract]
ABSTRACT: Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of movement symptoms (fluctuations, dyskinesia) after 2-3 years of the therapy. These complications may be reduced due to the constant (physiologic) stimulation of post-synaptic dopamine receptors that, to a certain degree, provides the drug stalevo, which contains levodopa and 2 enzyme inhibitors, dopa decarboxylase (carbidopa) and catechol-O-methyltransferase (entacapone). The results of the study demonstrated beneficial effects of stalevo as compared to traditional therapy in patients with "wearing off" and "on-off" phenomena.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 02/2007; 107(12):21-4. · 0.12 Impact Factor
-
T T Batysheva,
L V Bagir,
E V Kostenko,
I Iu Artemova,
T V Vdovichenko,
P A Ganzhula,
E Iu Zhuravleva,
A M Ismailov,
L N Lisenker,
O V Nesterova,
O V Otcheskaia,
L D Rotor, A A Khozova,
A N Boĭko
[show abstract]
[hide abstract]
ABSTRACT: Ginos, a derivative of extract Ginkgo Biloba, was administered to 100 patients, aged from 45 to 80 years, mean age 62,3+/-0,7), in dosage 120 mg 3 times daily during 3 months in addition to somatic therapy. A patient's state was assessed before, during and after the treatment using clinical methods and a battery of psychometric scales and neuropsychological tests. A significant improvement of neurological and mental status was found in 90 (90%) of patients that was most distinctly observed in the dynamics of their global state and neurocognitive performance on the MMSE and other tests. The effect of the drug was less pronounced for affective disorders - depression and anxiety. The drug was well-tolerated by patients.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 02/2007; 107(9):55-9. · 0.12 Impact Factor
